Twist Bioscience SEC Filings

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 08/21/2025 to satisfy tax withholding on vesting restricted stock units. The Form 4 shows a sale of 238 shares at a price of $25.964 per share, leaving the reporting person with 49,542 shares beneficially owned after the transaction. The filing clarifies this was a mandatory "sell to cover" required by the issuer's equity incentive plan and not an independent trading decision by the reporting person.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of company stock on 08/21/2025. The Form 4 shows 619 shares were disposed of at a price of $25.964 per share as a sell-to-cover transaction to satisfy tax withholding on vested Restricted Stock Units. After the transaction the reporting person beneficially owned 125,729 shares, which the filing notes includes shares acquired under the company Employee Stock Purchase Plan that were exempt under Rule 16b-3. The form was signed by an attorney-in-fact on 08/25/2025.

Twist Bioscience Corp (TWST) reporting person Adam Laponis, Chief Financial Officer, filed a Form 4 disclosing a non-discretionary sale of 918 shares of common stock on 08/21/2025 at a reported price of $25.964 per share. The filing states these shares were sold to satisfy tax withholding obligations associated with the vesting of restricted stock units under the companys equity plans, described as a mandatory "sell to cover" and not a discretionary trade.

Following the transaction, the reporting person beneficially owns 102,917 shares, which includes shares purchased under the companys Employee Stock Purchase Plan as noted in the filing. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Laponis and contains explanatory notes clarifying the nature of the sale and the ESPP exemption.

Patrick John Finn, President and COO of Twist Bioscience Corporation (TWST), reported a non-discretionary sale of 1,840 shares of Twist common stock on 08/21/2025 at a price of $25.964 per share. The filing states these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units and were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 233,529 shares, which the filing notes includes shares acquired under the company’s Employee Stock Purchase Plan in an exempt transaction. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Finn on 08/25/2025.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corporation (TWST), reported a sale of 521 shares of TWST common stock on 08/21/2025 at a price of $25.964 per share. The Form 4 notes the sale was a "sell to cover" transaction required to satisfy tax withholding upon vesting of Restricted Stock Units and not a discretionary trade. After the transaction the reporting person beneficially owned 103,306 shares directly. The form was signed by an attorney-in-fact, Kendra Fox, on 08/25/2025.

Twist Bioscience (TWST) filed a Form 144 reporting a proposed sale of 853 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $23,620.68 and an approximate sale date of 08/25/2025. The filing shows these 853 shares were acquired on 08/22/2025 upon restricted stock vesting as part of compensation and were paid for on 08/22/2025. The filer previously sold small blocks of common stock on 06/06/2025, 08/04/2025, and 08/21/2025 for gross proceeds of $7,143.66, $5,275.72, and $6,179.48 respectively. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information.

The Form 144 filed for TWST reports a proposed sale of 2,716 shares of common stock through Fidelity Brokerage Services on 08/21/2025 with an aggregate market value of $70,518.77. The shares were acquired on 08/20/2025 via restricted stock vesting from the issuer and payment is noted as compensation. The filing also lists five sales by Emily M. Leproust in the past three months totaling 12,711 shares with combined gross proceeds of $398,886.65 on dates from 05/21/2025 through 08/04/2025. The notice includes the standard signature representation about absence of undisclosed material adverse information.

Form 144 filed for Twist Bioscience Corporation (TWST) reporting an intended sale of common stock. The notice shows 1,840 shares to be sold through Fidelity Brokerage Services with an aggregate market value of $47,774.13 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 via restricted stock vesting and relate to compensation. The issuer has 60,360,925 shares outstanding per the form. Recent disposals by the same person, Patrick Finn, are listed: 1,877 shares (05/21/2025, $55,835.87), 209 shares (07/02/2025, $7,564.36), 2,232 shares (07/23/2025, $79,773.02), and 3,189 shares (08/04/2025, $90,453.11).

Twist Bioscience (TWST) filed a Form 144 disclosing a proposed sale of 619 common shares with an aggregate market value of $16,071.84, to be sold approximately on 08/21/2025 on NASDAQ. The shares were acquired on 08/20/2025 upon restricted stock vesting and were issued as compensation. The filer reports prior sales by the same person, Paula Green, totaling 3,174 shares across five transactions between 05/21/2025 and 08/04/2025, producing gross proceeds of $97,059.51. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.